Dulaglutide — sold as Trulicity — is one of the original once-weekly GLP-1 receptor agonists, and it built its evidence base as a type-2 diabetes drug, not a weight-loss one. That distinction matters. Its glycemic effect is solid and its cardiovascular benefit is genuine, but its effect on body weight is modest — a few kilograms — which is why people whose main goal is weight loss are usually pointed toward different drugs. Here is what the trials actually reported.
What dulaglutide is — and what it is approved for
Dulaglutide is a GLP-1 receptor agonist: it mimics the gut hormone GLP-1 to stimulate glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and blunt appetite. It is given as a once-weekly subcutaneous injection. Its FDA-approved indications are to improve glycemic control in adults and pediatric patients aged 10 and older with type-2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type-2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.[1] It is not approved for chronic weight management. Any weight loss on Trulicity is a secondary effect of the drug’s appetite and gastric actions, not the indication it is prescribed under.
The glycemic evidence: AWARD-6
The AWARD program is the set of phase-3 trials that established dulaglutide in diabetes. AWARD-6 is one of the most informative: it pitted once-weekly dulaglutide 1.5 mg directly against once-daily liraglutide 1.8 mg in metformin-treated adults with type-2 diabetes. Dulaglutide lowered HbA1c by about 1.4 percentage points and was statistically non-inferior to liraglutide on that endpoint — a strong glycemic showing against a well-regarded comparator.[2]On weight, dulaglutide produced about 2.9 kg of loss, slightly less than liraglutide’s roughly 3.6 kg. So even measured against another daily GLP-1, the weight effect was in the low-single-digit kilograms — useful, but not dramatic.
Pushing the dose: AWARD-11
Trulicity was later studied at higher doses to see whether more drug meant more benefit. AWARD-11 compared dulaglutide 1.5 mg, 3.0 mg, and 4.5 mg in metformin-treated type-2 diabetes. Both higher doses beat 1.5 mg on HbA1c, with the 4.5 mg dose giving the largest reduction, and weight loss rose stepwise with dose — reaching roughly 4.6 kg at 4.5 mg versus about 3.0 kg at 1.5 mg.[3] The pattern is the honest ceiling for this molecule: escalating the dose helps glucose and nudges weight upward, but even the maximum dose lands in the single-digit-kilogram range — well short of what the obesity-specific GLP-1s deliver.
The hard-outcome win: REWIND
Where dulaglutide is genuinely impressive is cardiovascular risk. REWIND randomized 9,901 adults with type-2 diabetes — the majority without established cardiovascular disease, making it largely a primary-prevention population — to dulaglutide or placebo and followed them for a median of about 5.4 years. Dulaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) by about 12% (hazard ratio 0.88).[4] That is a proven benefit on outcomes patients actually care about, and it is the basis for the drug’s cardiovascular indication. The weight difference in REWIND, by contrast, was modest — on the order of 1.5 kg — reinforcing that this is a cardiometabolic diabetes drug, not a weight-loss agent.
Why weight-loss seekers get steered elsewhere
The clearest way to see dulaglutide’s weight ceiling is the one time it was tested head-to-head against semaglutide. In SUSTAIN-7, dulaglutide 1.5 mg produced about 3.0 kg of weight loss versus 6.5 kg for semaglutide (Ozempic) 1.0 mg — roughly half — and semaglutide also lowered HbA1c more.[5] We cover that comparison in full in Trulicity vs Ozempic. And even Ozempic’s numbers are eclipsed by the drugs built and approved specifically for weight: in the STEP program, semaglutide 2.4 mg (Wegovy) cut body weight by about 15%, as detailed in the semaglutide weight-loss trials, and the dual GIP/GLP-1 agonist tirzepatide (Zepbound) went further still — see tirzepatide vs semaglutide. Against a roughly 15–21% obesity benchmark, dulaglutide’s few kilograms simply are not in the same class. That is why a clinician whose patient’s primary goal is weight loss — rather than blood-sugar control — will typically reach for Wegovy or Zepbound instead of Trulicity.
The honest bottom line
Dulaglutide is an effective, well-established once-weekly diabetes drug: it lowers HbA1c reliably, its higher doses add incremental glycemic and weight benefit, and REWIND gives it a real, outcome-proven cardiovascular indication. What it is not is an obesity drug. Its weight effect — a few kilograms — is a genuine secondary benefit for someone with diabetes, but it is far below the newer weight-specific GLP-1 and dual agonists. If blood sugar and heart risk are the target, Trulicity earns its place; if the goal is weight loss, the evidence points elsewhere.
This article is general scientific information, not medical advice. Dulaglutide (Trulicity) is a prescription drug approved for type-2 diabetes, not weight loss; decisions about starting, dosing, or switching GLP-1 medications should be made with a licensed clinician who knows your full medical history.